R

Relmada Therapeutics
D

RLMD

0.69000
USD
-0.01
(-1.46%)
مغلق
حجم التداول
31,095
الربح لكل سهم
-3
العائد الربحي
-
P/E
-0
حجم السوق
22,902,219
أصول ذات صلة
AZN
AZN
-0.220
(-0.31%)
70.750 USD
BAC
BAC
0.825
(1.87%)
45.050 USD
BNTX
BNTX
-0.480
(-0.46%)
104.480 USD
GS
GS
10.79
(1.73%)
635.36 USD
GSK
GSK
-1.075
(-2.71%)
38.640 USD
JNJ
JNJ
-1.620
(-1.06%)
150.730 USD
JPM
JPM
4.45
(1.65%)
273.95 USD
MRK
MRK
1.000
(1.28%)
79.290 USD
MRNA
MRNA
-0.145
(-0.57%)
25.410 USD
N
NVAX
-0.19500
(-3.00%)
6.30000 USD
PFE
PFE
-0.110
(-0.46%)
23.885 USD
V
V
-17.52
(-4.90%)
340.32 USD
المزيد
الأخبار المقالات

العنوان: Relmada Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous systemdiseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment ofdepression and other potential indications.